Literature DB >> 12430673

The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.

Pablo Menéndez1, Maria D Caballero, Felipe Prosper, Maria C Del Cañizo, Jose A Pérez-Simón, Maria V Mateos, Maria J Nieto, Mercedes Corral, Mercedes Romero, Javier García-Conde, Maria A Montalbán, Jesus F San Miguel, Alberto Orfao.   

Abstract

BACKGROUND: Effects of mobilization regimen on the composition of leukapheresis products (LPs) and on hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation (PBPCT) are not well known. STUDY DESIGN AND METHODS: The effects of three different mobilization regimens--stem cell factor (SCF) plus granulocyte colony stimulating factor (G-CSF) plus cyclophosphamide (CCP), G-CSF alone, and G-CSF plus CCP--on the composition of LPs from patients with nonhematologic PBPC malignancies compared to LPs from G-CSF-mobilized healthy donors and normal marrow (BM) samples were analyzed. The impact of LP composition on both short- and long-term engraftment after autologous PBPCT was also evaluated.
RESULTS: The most effective regimen for mobilization of CD34+ hematopoietic progenitor cells (HPCs) into peripheral blood was SCF, G-CSF, and CCP, providing the highest numbers of all CD34+ HPCs subsets analyzed. Patients mobilized with SCF plus G-CSF plus CCP showed the highest numbers of neutrophils and monocytes, whereas the highest numbers of lymphocytes and NK cells were observed in LPs from G-CSF-mobilized patients. The overall number of CD34+ HPCs was the strongest factor for predicting recovery of platelets, whereas the number of myelomonocytic-committed CD34+ precursors was the most powerful independent prognostic factor for WBC and neutrophil recovery. The overall number of CD4+ T cells returned showed an independent prognostic value for predicting the occurrence of infections, during the first year after transplant.
CONCLUSIONS: The use of different mobilization regimens modifies the overall number of CD34+ HPCs obtained during leukapheresis procedures, and also affects both the absolute and the relative composition of the LPs in different CD34+ and CD34- cell subsets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430673     DOI: 10.1046/j.1537-2995.2002.00190.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Nodal/Activin signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage.

Authors:  Veronica Ramos-Mejia; Gustavo J Melen; Laura Sanchez; Ivan Gutierrez-Aranda; Gertrudis Ligero; Jose L Cortes; Pedro J Real; Clara Bueno; Pablo Menendez
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Aerobic exercise in humans mobilizes HSCs in an intensity-dependent manner.

Authors:  Jeff M Baker; Joshua P Nederveen; Gianni Parise
Journal:  J Appl Physiol (1985)       Date:  2016-11-23

3.  Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function.

Authors:  Damia Romero-Moya; Clara Bueno; Rosa Montes; Oscar Navarro-Montero; Francisco J Iborra; Luis Carlos López; Miguel Martin; Pablo Menendez
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

4.  The ROCK inhibitor Y-27632 negatively affects the expansion/survival of both fresh and cryopreserved cord blood-derived CD34+ hematopoietic progenitor cells: Y-27632 negatively affects the expansion/survival of CD34+HSPCs.

Authors:  Clara Bueno; Rosa Montes; Pablo Menendez
Journal:  Stem Cell Rev Rep       Date:  2010-06       Impact factor: 5.739

5.  Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.

Authors:  Ivetta Danylesko; Rina Sareli; Nira Varda-Bloom; Ronit Yerushalmi; Noga Shem-Tov; Hila Magen; Avichai Shimoni; Arnon Nagler
Journal:  Int J Hematol       Date:  2021-07-02       Impact factor: 2.490

6.  Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.

Authors:  R Montes; V Ayllón; C Prieto; A Bursen; C Prelle; D Romero-Moya; P J Real; O Navarro-Montero; C Chillón; R Marschalek; C Bueno; P Menendez
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

7.  A promoter DNA demethylation landscape of human hematopoietic differentiation.

Authors:  Vincenzo Calvanese; Agustín F Fernández; Rocío G Urdinguio; Beatriz Suárez-Alvarez; Cristina Mangas; Vicente Pérez-García; Clara Bueno; Rosa Montes; Verónica Ramos-Mejía; Pablo Martínez-Camblor; Cecilia Ferrero; Yassen Assenov; Christoph Bock; Pablo Menendez; Ana Clara Carrera; Carlos Lopez-Larrea; Mario F Fraga
Journal:  Nucleic Acids Res       Date:  2011-09-12       Impact factor: 16.971

8.  Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors.

Authors:  Verónica Ramos-Mejía; Rosa Montes; Clara Bueno; Verónica Ayllón; Pedro J Real; René Rodríguez; Pablo Menendez
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.

Authors:  Belen Lopez-Millan; Diego Sanchéz-Martínez; Heleia Roca-Ho; Francisco Gutiérrez-Agüera; Oscar Molina; Rafael Diaz de la Guardia; Raúl Torres-Ruiz; Jose Luís Fuster; Paola Ballerini; Ute Suessbier; Cesar Nombela-Arrieta; Clara Bueno; Pablo Menéndez
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 11.528

10.  CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.

Authors:  Clara Bueno; Talia Velasco-Hernandez; Francisco Gutiérrez-Agüera; Samanta Romina Zanetti; Matteo L Baroni; Diego Sánchez-Martínez; Oscar Molina; Adria Closa; Antonio Agraz-Doblás; Pedro Marín; Eduardo Eyras; Ignacio Varela; Pablo Menéndez
Journal:  Leukemia       Date:  2019-02-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.